Geron Corp (GERN) Misses Q4 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Geron Corp (GERN) Misses Q4 EPS by 2c

Geron Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Milestones

March 10, 2022 4:06 PM EST

Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Expected in Early January 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business updates, upcoming milestones and financial results for the fourth quarter and year ended December 31, 2021. The Company ended 2021 with $212.7 million in cash and marketable securities, which the Company believes is sufficient to fund current operations through the end of the first quarter of 2023.

We made significant accomplishments... More